IL314694A - Methods and compositions for preventing or delaying type 1 diabetes - Google Patents

Methods and compositions for preventing or delaying type 1 diabetes

Info

Publication number
IL314694A
IL314694A IL314694A IL31469424A IL314694A IL 314694 A IL314694 A IL 314694A IL 314694 A IL314694 A IL 314694A IL 31469424 A IL31469424 A IL 31469424A IL 314694 A IL314694 A IL 314694A
Authority
IL
Israel
Prior art keywords
diabetes
compositions
preventing
methods
delaying type
Prior art date
Application number
IL314694A
Other languages
Hebrew (he)
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Priority claimed from US18/321,964 external-priority patent/US20230382993A1/en
Publication of IL314694A publication Critical patent/IL314694A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL314694A 2022-05-24 2023-05-23 Methods and compositions for preventing or delaying type 1 diabetes IL314694A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263345365P 2022-05-24 2022-05-24
US202263367992P 2022-07-08 2022-07-08
US202263382382P 2022-11-04 2022-11-04
PCT/US2023/067357 WO2023230476A1 (en) 2022-05-24 2023-05-23 Methods and compositions for preventing or delaying type 1 diabetes
US18/321,964 US20230382993A1 (en) 2022-05-24 2023-05-23 Methods and compositions for preventing or delaying type 1 diabetes
TW112119143A TW202411250A (en) 2022-05-24 2023-05-23 Methods and compositions for preventing or delaying type 1 diabetes

Publications (1)

Publication Number Publication Date
IL314694A true IL314694A (en) 2024-10-01

Family

ID=88920022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314694A IL314694A (en) 2022-05-24 2023-05-23 Methods and compositions for preventing or delaying type 1 diabetes

Country Status (7)

Country Link
JP (1) JP2025517856A (en)
KR (1) KR20250017195A (en)
AU (2) AU2023275531C1 (en)
CA (1) CA3256691A1 (en)
IL (1) IL314694A (en)
MX (1) MX2024008438A (en)
WO (1) WO2023230476A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN121568962A (en) * 2023-07-27 2026-02-24 普瑞文森生物有限公司 Method for treating type 1 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714733T3 (en) * 2011-05-21 2019-05-06 Macrogenics Inc CD3 BINDING MOLECULES ABLE TO BIND TO HUMAN AND NON-HUMAN CD3
IL322315A (en) * 2019-05-14 2025-09-01 Provention Bio Inc Methods and compositions for prevention of type 1 diabetes
AU2021287998B2 (en) * 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes

Also Published As

Publication number Publication date
AU2023275531C1 (en) 2026-01-22
CA3256691A1 (en) 2023-11-30
KR20250017195A (en) 2025-02-04
WO2023230476A1 (en) 2023-11-30
MX2024008438A (en) 2024-09-18
AU2023275531B2 (en) 2025-07-17
JP2025517856A (en) 2025-06-12
AU2023275531A1 (en) 2024-07-18
AU2025252600A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
IL314694A (en) Methods and compositions for preventing or delaying type 1 diabetes
IL307721A (en) Compositions and methods for inhibiting complement component 3 expression
IL316981A (en) Methods and compositions for preventing or treating food allergies
PL4069278T3 (en) Methods and compositions for the prevention of type 1 diabetes
HK40122704A (en) Methods and compositions for preventing or delaying type 1 diabetes
HK40095886A (en) Methods and compositions for preventing type 1 diabetes
EP4164689A4 (en) Methods and compositions for preventing type 1 diabetes
GB202215065D0 (en) Compositions and uses thereof
GB202209335D0 (en) Compositions and uses thereof
EP4054558A4 (en) Methods and compositions for type 2 diabetes therapy
EP4058043A4 (en) Compositions and methods for treating or preventing crohn's disease
HK40089082A (en) Methods and compositions for the treatment and prevention of type 1 diabetes
HK40105632A (en) Compositions and methods for inhibiting complement component 3 expression
IL318634A (en) Haemorrhage inhibiting compositions and methods involving the same
GB202216227D0 (en) Composition and uses thereof
GB2635318B (en) Methods and compositions
CA3284237A1 (en) Compositions and methods for treating diabetes
HK40087822A (en) Compositions and methods for treating or preventing pulmonary hypertension
GB202410495D0 (en) Composition and uses thereof
GB202402961D0 (en) Composition and uses thereof
CA3288518A1 (en) Modified trems, compositions, and related methods thereof
HK40101234A (en) Methods and compositions for high-potency polypeptide-based protein inhibition
EP4314018A4 (en) Methods and compositions for high-potency polypeptide-based protein inhibition
HK40119848A (en) Compositions and methods for inhibiting complement factor b
GB202306393D0 (en) Trna-based methods and related compositions